Technology

Technology

Our Platform 

Our proprietary, autologous fibroblast technology platform is the foundation for developing disease-modifying therapies for rare diseases with high unmet medical needs

Our Differentiated Cell and Gene Therapy Approach

Castle Creek Biosciences’ autologous fibroblast technology uses our patented manufacturing process, which involves collecting small skin biopsies from patients, isolating cells and expanding them in culture, transducing the fibroblast cells with an integrative lentiviral vector to express a targeted protein, followed by continued expansion of the gene-modified cells in culture. The cells are then locally administered to the disease site with the goal of expressing the target protein in the desired region in order to restore its functionality. As part of this process, Castle Creek Biosciences also creates a personalized cell bank of genetically modified autologous fibroblasts that can be stored cryogenically, serving as a repository for the patient’s long term drug product needs. 

Our entire fibroblast platform is done autologously. This approach allows us to avoid many of the rejection concerns presented with allogeneic cells and results in a higher likelihood of efficacy.

John Maslowski, Chief Scientific Advisor

The Science of Autologous Fibroblasts

Fibroblasts, the most common cell in skin and connective tissue, are responsible for synthesizing extracellular matrix proteins, including collagen, that provide structure and support to the skin. Castle Creek Biosciences is leveraging these clinical benefits of fibroblasts as the basis of our personalized, autologous fibroblast technology platform.

science of autologous fibroblasts

Readily Sourced from Skin

Fibroblasts are found in all skin and connective tissue and can be isolated from the skin and expanded in culture.  The ability to genetically modify fibroblasts has been well documented in scientific literature .

Functionally Critical

Fibroblasts synthesize the structural framework of tissue.

Ideal Delivery Vehicle

Fibroblasts have unique capabilities for localized (vs. systemic) delivery to gene targets in the skin and connective tissue.